July 28 (Reuters) – A U.S. judge said on Tuesday that Novo Nordisk must face part of a lawsuit accusing it of defrauding shareholders about a clinical trial for its weight loss and diabetes treatment CagriSema.
Investors in Novo Nordisk’s American depositary receipts said their securities plummeted in value after the market learned that the Danish drugmaker changed its usual protocols for the clinical trial, known as Redefine 1, by letting participants control their own CagriSema dosages.
While dismissing claims based on many alleged misleading statements and omissions, U.S. District Judge Robert Kirsch in Trenton, New Jersey said investors could pursue claims over Novo Nordisk statements related to CagriSema’s “tolerability” and Redefine 1’s related clinical protocols.
(Reporting by Jonathan Stempel in New York; Editing by Mark Porter and Chizu Nomiyama)
Comments